語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
到查詢結果
[ subject:"Health care management." ]
切換:
標籤
|
MARC模式
|
ISBD
Cost-effectiveness of genetic testin...
~
Gopalakrishnan, Vancheswaran.
FindBook
Google Book
Amazon
博客來
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting./
作者:
Gopalakrishnan, Vancheswaran.
面頁冊數:
39 p.
附註:
Source: Masters Abstracts International, Volume: 52-04.
Contained By:
Masters Abstracts International52-04(E).
標題:
Health care management. -
電子資源:
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1549596
ISBN:
9781303619724
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting.
Gopalakrishnan, Vancheswaran.
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting.
- 39 p.
Source: Masters Abstracts International, Volume: 52-04.
Thesis (M.P.H.)--The University of Texas School of Public Health, 2013.
This item is not available from ProQuest Dissertations & Theses.
There is a great interest in delivering personalized cancer care for patients. It has been generally accepted in cancers like CML, and in theory this strategy could even be used in the Phase 1 setting. The value of this strategy will be determined by the increased benefit of the testing against the testing's associated increased costs. My goal in this thesis was to develop a method for determining this value in a cohort of metastatic melanoma patients who participated in phase I clinical trials at M.D. Anderson Cancer Center. The clinical parameter of benefit used was time to treatment failure (TTF) and the charges were those accrued by patients during their participation on the trial. TTF was defined as length of time on a trial without progression. Charge data were extracted from the MD Anderson business data base. In patients where molecular analysis was obtained and used to guide eligibility for targeted phase 1 agents, patients experienced an increase in TTF of 2 months (p=0.099) when compared to patients who were enrolled in a trial without prior molecular analyses. This however was not the primary concern of this study. Using these charges and clinical data, value was determined. The charges added by the testing were of greater influence than was the small, but significant added clinical benefit. Value, not cost alone, ought to be the parameter of importance when determining whether genetic tumor testing will become part of routine clinical care. This methodology is a way to make that determination and can be applied to each individual clinical setting.
ISBN: 9781303619724Subjects--Topical Terms:
2122906
Health care management.
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting.
LDR
:02582nmm a2200289 4500
001
2064476
005
20151115152126.5
008
170521s2013 eng d
020
$a
9781303619724
035
$a
(MiAaPQ)AAI1549596
035
$a
AAI1549596
040
$a
MiAaPQ
$c
MiAaPQ
100
1
$a
Gopalakrishnan, Vancheswaran.
$3
3179071
245
1 0
$a
Cost-effectiveness of genetic testing in metastatic melanoma patients in the Phase-1 setting.
300
$a
39 p.
500
$a
Source: Masters Abstracts International, Volume: 52-04.
500
$a
Advisers: Leonard A. Zwelling; David S. Lopez.
502
$a
Thesis (M.P.H.)--The University of Texas School of Public Health, 2013.
506
$a
This item is not available from ProQuest Dissertations & Theses.
520
$a
There is a great interest in delivering personalized cancer care for patients. It has been generally accepted in cancers like CML, and in theory this strategy could even be used in the Phase 1 setting. The value of this strategy will be determined by the increased benefit of the testing against the testing's associated increased costs. My goal in this thesis was to develop a method for determining this value in a cohort of metastatic melanoma patients who participated in phase I clinical trials at M.D. Anderson Cancer Center. The clinical parameter of benefit used was time to treatment failure (TTF) and the charges were those accrued by patients during their participation on the trial. TTF was defined as length of time on a trial without progression. Charge data were extracted from the MD Anderson business data base. In patients where molecular analysis was obtained and used to guide eligibility for targeted phase 1 agents, patients experienced an increase in TTF of 2 months (p=0.099) when compared to patients who were enrolled in a trial without prior molecular analyses. This however was not the primary concern of this study. Using these charges and clinical data, value was determined. The charges added by the testing were of greater influence than was the small, but significant added clinical benefit. Value, not cost alone, ought to be the parameter of importance when determining whether genetic tumor testing will become part of routine clinical care. This methodology is a way to make that determination and can be applied to each individual clinical setting.
590
$a
School code: 0219.
650
4
$a
Health care management.
$3
2122906
650
4
$a
Epidemiology.
$3
568544
690
$a
0769
690
$a
0766
710
2 0
$a
The University of Texas School of Public Health.
$b
Epidemiology & Disease Control.
$3
1019542
773
0
$t
Masters Abstracts International
$g
52-04(E).
790
$a
0219
791
$a
M.P.H.
792
$a
2013
793
$a
English
856
4 0
$u
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1549596
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9297134
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入